This week in Otolaryngology (ENT)
Nov 19, 2026
Zopapogene Imadenovec-drba Treatment for Adults With Recurrent Respiratory Papillomatosis: A Review.
In the pivotal nonrandomized trial, 18 of 35 adults with recurrent respiratory papillomatosis needed no surgery for a year after zopapogene imadenovec-drba, now recommended first-line.
JAMA Otolaryngology-Head & Neck Surgery · 2026 · PubMed
This week’s highlights
Read the weekly briefing
This AudioScholar briefing is generated by artificial intelligence from PubMed abstracts for healthcare professionals and is not medical advice.
This week: a newly approved immunotherapy moves into routine care for adult papillomatosis, a randomized trial tests an appetite drug against weight loss during head and neck radiotherapy, and a pooled analysis resets malignancy risk in inverted papilloma.
Welcome to This Week in Otolaryngology. We're covering 10 papers this week: 3 in depth, 4 in brief, 3 quick signals.
In JAMA Otolaryngology-Head and Neck Surgery, Norberg, Misono and Allen publish a narrative review of zopapogene imadenovec-drba for adults with recurrent respiratory papillomatosis [1]. The context is a shift in standard care: the drug has Food and Drug Administration approval, and the RRP Foundation Position Statement now recommends it as first-line treatment. The review goes beyond the trial reports to cover why the pivotal trial was designed as it was, how to select patients, how to administer the drug, how to handle perioperative management, and how to approach specific populations. The efficacy data behind it come from a phase 1/2 nonrandomized trial in which 18 of 35 patients, about half of the cohort, achieved a complete response, defined as no clinically indicated surgical procedure in the 12 months after treatment. The main limitation is that the evidence base is a single small, nonrandomized trial, and this paper is a narrative review rather than a systematic one. What it adds is practical implementation guidance for otolaryngologists and medical oncologists, for a disease that has until now been managed almost entirely by repeated surgery.
In Head and Neck, Muangwong and colleagues report a multicentre, open-label randomized trial of megestrol acetate to prevent weight loss during radiotherapy [2]. They enrolled 102 patients with non-nasopharyngeal head and neck squamous cell carcinoma and assigned them to megestrol plus standard care or standard care alone, where standard care meant nutritional counselling, symptom management and feeding tubes when indicated. The primary endpoint was weight change from baseline to six weeks after radiotherapy. Patients on megestrol gained about two kilograms on average, while controls lost close to two kilograms, a statistically significant difference. The weight gained was mainly fat mass, with no significant difference in muscle mass, and quality of life was similar between the groups. The most important limitations are the open-label design and an endpoint that is a surrogate: the abstract reports no effect on treatment tolerance or cancer outcomes. The authors conclude megestrol may serve as an adjunct to supportive care. As randomized evidence it is the firmest paper this week, though the gain it shows is in weight, largely fat, rather than in function or survival.
Also on metabolism and head and neck cancer, Hunter and colleagues in JAMA Otolaryngology-Head and Neck Surgery ran a retrospective cohort study using the TriNetX Global Collaborative Network, asking whether GLP-1 receptor agonists are associated with survival in head and neck squamous cell carcinoma [3]. The cohort included 4,532 adults. Users of these drugs had a hazard of death roughly half that of controls, with the association present at one, three and five years. The pattern held across oral cavity, oropharynx and larynx. Patients using a GLP-1 receptor agonist together with metformin had an even lower hazard, about sixty percent lower at five years. The limitation is the design: a retrospective database comparison cannot separate a drug effect from differences in who gets prescribed these agents, and effects this large in observational data call for caution. The authors themselves describe the findings as associations that need prospective and interventional confirmation. Set beside the megestrol trial, the two papers share a metabolic focus, but only the trial is randomized, and it measured weight rather than survival.
Now, four in brief.
In Head and Neck, de Castro and colleagues performed a systematic review and meta-analysis of adverse pathological features in early-stage, node-negative oral cavity squamous cell carcinoma [4]. Forty studies with over fifteen thousand patients were included, thirty of them pooled. Perineural invasion roughly doubled the hazard of worse disease-free survival and was linked to about four times the odds of nodal metastasis. Depth of invasion, lymphovascular invasion and worst pattern of invasion were also each associated with nodal metastasis, but with overlapping estimates. Associations with survival were imprecise. The certainty of evidence was moderate at best and low or very low for most associations, and the authors state the data do not allow the predictors to be ranked.
In The Laryngoscope, Fu and colleagues used the National Cancer Database from 2015 to 2022 to study positive surgical margins in 753 adults having definitive surgery for node-negative sinonasal cancer [5]. About a third of patients had positive margins, and the rate rose over the period to just over forty percent. Predictors included advanced T stage, maxillary sinus origin, higher comorbidity, conversion to open surgery, which roughly doubled the risk, and Native American race, which nearly tripled it. Positive margins independently predicted worse overall survival, with roughly double the hazard of death in the matched analysis. This is retrospective registry data, so the trends and predictors are associations.
Also in The Laryngoscope and also in the sinonasal tract, McHugh and colleagues pooled 68 studies of more than seven thousand patients with inverted papilloma [6]. The pooled prevalence of any malignancy was about 6 percent, made up of synchronous carcinoma in about 4 percent and metachronous carcinoma in about 1 percent. Recurrence was about 18 percent. The authors note these estimates sit below the figures most often cited, and offer them as a benchmark for counselling and surveillance. The estimates rest on pooled observational series with random-effects modelling.
In Otolaryngology-Head and Neck Surgery, Haji and colleagues used the TriNetX United States network to compare 221 children with chronic rhinosinusitis with nasal polyps starting dupilumab against 221 matched controls starting a steroid burst [7]. Over a year, the dupilumab group had fewer episodes of acute sinusitis, about 5 percent against 14 percent, fewer steroid bursts, and endoscopic sinus surgery rates that were fifty percent lower. Emergency visits and admissions did not differ significantly. Polyp diagnoses were documented more often in the dupilumab group, which points to residual differences between cohorts, and the design is retrospective.
Three quick signals.
The International Surgical Sleep Society, in a position statement led by Dhanda Patil in Otolaryngology-Head and Neck Surgery, reviewed 43 studies of hypoglossal nerve stimulation [8]. Surgical response ranged from about two thirds to over eighty percent, nightly use was roughly six to eight hours, and predictors of success were mixed. This is expert consensus built on a literature review.
On sleep apnea in a harder population, Altamimi and colleagues in The Laryngoscope reviewed 65 children with cerebral palsy undergoing adenotonsillectomy at one tertiary centre [9]. The obstructive apnea index fell from about 20 to about 8, and just over six in ten children reached an index under five, while 40 percent of children still needed noninvasive ventilation. It is a single-centre retrospective series.
In Head and Neck, a EUSICA and INSICA position paper led by de Ridder argues that squamous cell carcinoma of the nasal vestibule is a distinct entity [10]. It calls for its own ICD-O-3 subsite and adoption of the New Rome T classification, which was validated in 609 patients from 21 centres. This is expert consensus, and molecular data are not yet available.
Stepping back across this week's papers, most of the evidence comes from retrospective databases, pooled observational series and expert consensus, while the single randomized trial measured a surrogate rather than a hard outcome. The largest survival associations sit in the designs least able to establish cause, and several pooled analyses grade their own certainty as low. Even the treatment now recommended first-line for papillomatosis rests on one small nonrandomized trial.
If you only have time for one paper this week, make it the review of zopapogene imadenovec-drba for adult recurrent respiratory papillomatosis [1]. It addresses how a newly recommended first-line nonsurgical therapy moves from a single trial into everyday practice for a disease long defined by repeated operations.
That's your roundup for This Week in Otolaryngology. The full transcript and references are available on the episode page. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague, in any specialty, who never has time to keep up with the literature. Tell them about AudioScholar: a ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.
This is an automated summary generated by artificial intelligence, which can make mistakes. Use it to choose which papers to read in full.
Get Otolaryngology (ENT) every week
By email, Spotify, Apple or any podcast app.
Spot something worth flagging?